Anthem Biosciences Limited is one of India’s leading Contract Research, Development, and Manufacturing Organizations (CRDMO). Headquartered in Bangalore, it provides end-to-end services across the pharmaceutical value chain. From discovery biology to commercial-scale manufacturing, the company caters to over 550 clients across 44 countries. Alongside its CRDMO operations, Anthem is also engaged in the manufacture and sale of specialty ingredients used in pharmaceuticals, cosmetics, and nutraceuticals.
The company’s meteoric rise has been fueled by its advanced research infrastructure, strong intellectual property portfolio, growing international presence, and a deep commitment to innovation and compliance. In recent years, it has emerged as a preferred outsourcing partner for biotech and pharma companies looking for high-quality, cost-effective solutions from India.
Strategic Partnership with DavosPharma
One of the major developments in FY25 was Anthem’s expanded partnership with DavosPharma, a U.S.-based provider of drug development and sourcing services. This strategic alliance was aimed at deepening Anthem’s reach in the U.S. market, which is home to the world’s largest base of biotech startups and pharmaceutical companies.
DavosPharma has been associated with Anthem since 2008 when it invested in the company. The renewed collaboration now allows Anthem to leverage DavosPharma’s local network and industry insights. Through this partnership, Anthem is better positioned to pitch its end-to-end CRDMO services to North American clients, especially smaller biotech companies that demand speed, agility, and technical depth. This move has already started yielding results as the company secured new clients and expanded ongoing projects in the U.S.
End-to-End Capabilities Across Modalities
Anthem’s core strength lies in its ability to serve as a one-stop CRDMO across both small and large molecule segments. Its service offerings include:
Small Molecules:
-
Process Research & Development
-
Analytical Method Development
-
Custom Synthesis
-
Scale-Up & Commercial Manufacturing
-
Regulatory Support
Large Molecules and Biologics:
-
Fermentation & Downstream Processing
-
Mammalian and Microbial Cell Culture
-
Development of Peptides, Oligonucleotides, RNAi, and Lipids
-
Conjugation Chemistry for ADCs
This broad portfolio enables the company to support drug development from discovery to market launch. Anthem is also a pioneer in India for adopting continuous-flow chemistry and biotransformation-based processes, which improve efficiency and reduce environmental impact.
State-of-the-Art Infrastructure
Anthem’s facilities span multiple campuses in and around Bangalore. These include:
Unit I – Bommasandra:
This facility houses R&D and small-scale production for custom synthesis. It has undergone multiple successful inspections by global regulatory authorities.
Unit II – Harohalli:
Focused on commercial-scale manufacturing, this facility is approved by major regulatory bodies including US FDA, PMDA (Japan), ANVISA (Brazil), and TGA (Australia). It handles both chemical synthesis and fermentation-based production.
Unit III – Upcoming Facility:
Slated to be fully operational in FY26, Unit III will further expand Anthem’s capacity and capabilities. Once completed, it will take the company’s annual custom synthesis capacity to 425 kilo litres (kL) and fermentation capacity to 182 kL—making it one of the largest in India’s CRDMO sector.
Together, these facilities allow Anthem to handle a wide range of projects from milligram to ton-scale production while ensuring regulatory compliance and quality standards.
Robust Intellectual Property Portfolio
Innovation is central to Anthem’s strategy. As of FY25, the company held:
-
1 Indian patent
-
7 international patents
-
17 additional patent applications filed globally
These patents span multiple domains, including novel synthetic routes, biologic drug modalities like RNAi and peptides, and specialized fermentation processes. The company’s R&D team comprises over 1,000 scientists, including more than 35 PhDs. They are supported by sophisticated labs equipped with high-end instrumentation, allowing cutting-edge research in chemistry, biology, and analytics.
This intellectual property not only reinforces Anthem’s technical leadership but also strengthens its value proposition for global clients who seek proprietary processes or IP development support.
Financial Performance & Growth Trajectory
Anthem has shown impressive financial growth over the past five years. Its revenue crossed ₹1,000 crore in FY21 and continued to rise steadily. In FY25, approximately 82% of its revenue came from CRDMO services, while the remaining was contributed by specialty ingredients.
The company has a well-diversified client base, though the top 10 customers accounted for about 77% of revenues in FY25. Around 87% of its clients are small and emerging biopharma companies—an important segment that is growing faster than traditional large pharma.
Moreover, the company recently filed for an IPO to raise nearly ₹34 billion. The proceeds are planned for capacity expansion, debt repayment, and R&D investments. This move indicates Anthem’s intent to capitalize on the growing global demand for outsourcing drug development and manufacturing.
Regulatory Excellence and Global Compliance
One of Anthem’s biggest assets is its track record of regulatory compliance. Its facilities have been audited by key international agencies like:
-
US Food and Drug Administration (FDA)
-
Japan’s PMDA
-
Brazil’s ANVISA
-
Australia’s TGA
In addition to these, Anthem also holds certifications like ISO 9001, ISO 14001, OHSAS 18001, GLP (Good Laboratory Practice), and AAALAC (for animal studies).
This regulatory pedigree assures clients that their projects will meet global quality standards, which is especially important for drugs that need to be registered or launched in regulated markets.
Specialty Ingredients Segment
Beyond its core CRDMO operations, Anthem also manufactures specialty ingredients used in cosmetics, nutraceuticals, and animal health. This business leverages the company’s deep expertise in fermentation and synthetic chemistry to create high-purity, performance-oriented ingredients.
Though smaller in size, this segment offers steady cash flow and complements Anthem’s overall capabilities. It also opens new markets and adds a layer of diversification to the company’s revenue mix.
Environmental and Social Responsibility
Anthem has made significant efforts in environmental sustainability, safety, and corporate social responsibility (CSR). It integrates green chemistry principles in its processes and invests in energy-efficient technologies.
In FY24, the company spent ₹8.66 crore on CSR activities, up from ₹5.99 crore in the previous year. These initiatives included:
-
Supporting education for underprivileged children
-
Rural healthcare projects
-
Clean drinking water programs
-
Women’s skill-building and employment initiatives
These actions reflect the company’s commitment to making a positive societal impact while achieving business growth.
Competitive Landscape
India’s CRDMO sector is highly competitive, with players like Syngene, GVK Biosciences, Sai Life Sciences, and Aragen Life Sciences. However, Anthem stands out due to its balanced focus on both small and large molecule services, patent-backed research, regulatory approvals, and expansion momentum.
Unlike companies that specialize in either discovery or manufacturing, Anthem provides an integrated approach, reducing time-to-market and complexity for clients. This full-spectrum service model is especially appealing to biotech startups and mid-sized pharma companies.
Future Outlook
Looking ahead, Anthem Biosciences is well-positioned for sustained growth. Its immediate priorities include:
-
Commissioning and scaling up the Unit III facility
-
Deepening its U.S. presence through the DavosPharma alliance
-
Expanding offerings in high-potency APIs, peptides, and biologics
-
Strengthening IP through R&D investments and global filings
-
Delivering profitable growth post-IPO
The increasing complexity of drug development, coupled with the rising cost of in-house R&D, is driving pharma companies to outsource more to partners like Anthem. With its strong foundation and ambitious roadmap, the company is set to benefit from this global outsourcing wave.
Conclusion
Anthem Biosciences has emerged as a force to reckon with in the global CRDMO space. Its integrated service model, strong technical foundation, and global regulatory compliance give it a unique edge. The partnership with DavosPharma, upcoming capacity expansions, and strong financials make it a compelling story not just within India, but in the global pharmaceutical supply chain.
As biotech and pharma companies continue to seek agile, innovative partners, Anthem is perfectly poised to meet this demand and shape the future of contract drug development and manufacturing.
